Related Experiment Video
Updated: Dec 14, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
A proposal for staging COVID-19 coagulopathy
Jecko Thachil1, Mary Cushman2, Alok Srivastava3
1Department of Haematology Manchester University Hospitals Manchester UK.
Insights
This study explores lung-centered hemostatic issues in Coronavirus disease 2019 (COVID-19) patients. It proposes staging COVID-19 coagulopathy and suggests tailored treatments for better outcomes.
Area of Science:
- Pulmonary Medicine
- Hematology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19) is linked to severe hypercoagulability.
- Critically ill COVID-19 patients experience thrombotic events despite anticoagulation.
Purpose of the Study:
- To identify the lungs as the primary site of COVID-19-related hemostatic dysfunction.
- To propose a staging system for COVID-19 coagulopathy using diagnostic markers.
- To suggest stage-specific therapeutic strategies for COVID-19-associated coagulopathy.
Main Methods:
- Review and synthesis of current literature on COVID-19 and coagulopathy.
- Analysis of diagnostic markers indicative of hypercoagulable states.
- Conceptual framework development for disease staging and treatment.
Main Results:
- The lungs are implicated as the central organ for COVID-19-induced hemostatic abnormalities.
- A proposed staging system for COVID-19 coagulopathy based on clinical and laboratory findings.
- Identification of potential therapeutic targets and treatment adjustments for different disease stages.
Conclusions:
- Understanding the lung's role in COVID-19 coagulopathy is crucial.
- A staged approach to managing COVID-19 coagulopathy may improve patient outcomes.
- Further research into targeted therapies for COVID-19-associated thrombosis is warranted.
Abstract:
Coronavirus disease 2019 (COVID-19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for staging COVID-19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Related Concept Videos
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care